1. Van der Bliek AM, Meyers MB, Biedler JL, Hes E, Borst P. A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain. EMBO J 1986;5:3201-8.

2. Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, Ilari A. Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules 2014;19:13976-89.

3. Hansen C, Tarabykina S, la Cour JM, Lollike K, Berchtold MW. The PEF family proteins sorcin and grancalcin interact in vivo and in vitro. FEBS Lett 2003;545:151-4.

4. Maki M, Kitaura Y, Satoh H, Ohkouchi S, Shibata H. Structures, functions and molecular evolution of the penta-EF-hand Ca2+-binding proteins. Biochim Biophys Acta 2002;1600:51-60.

5. Ilari A, Fiorillo A, Poser E, Lalioti VS, Sundell GN, Ivarsson Y, Genovese I, Colotti G. Structural basis of Sorcin-mediated calcium-dependent signal transduction. Sci Rep 2015;5:16828.

6. Ilari A, Johnson KA, Nastopoulos V, Verzili D, Zamparelli C, Colotti G, Tsernoglou D, Chiancone E. The crystal structure of the sorcin calcium binding domain provides a model of Ca2+-dependent processes in the full-length protein. J Mol Biol 2002;317:447-58.

7. Colotti G, Zamparelli C, Verzili D, Mella M, Loughrey CM, Smith GL, Chiancone E. The W105G and W99G sorcin mutants demonstrate the role of the D helix in the Ca(2+)-dependent interaction with annexin VII and the cardiac ryanodine receptor. Biochemistry 2006;45:12519-29.

8. Mella M, Colotti G, Zamparelli C, Verzili D, Ilari A, Chiancone E. Information transfer in the penta-EF-hand protein sorcin does not operate via the canonical structural/functional pairing. A study with site-specific mutants. J Biol Chem 2003;278:24921-8.

9. Zamparelli C, Ilari A, Verzili D, Giangiacomo L, Colotti G, Pascarella S, Chiancone E. Structure-function relationships in sorcin, a member of the penta EF-hand family. Interaction of sorcin fragments with the ryanodine receptor and an Escherichia coli model system. Biochemistry 2000;39:658-66.

10. Lalioti VS, Ilari A, O'Connell DJ, Poser E, Sandoval IV, Colotti G. Sorcin links calcium signaling to vesicle trafficking, regulates Polo-like kinase 1 and is necessary for mitosis. PLoS One 2014;9:e85438.

11. Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, Piscazzi A, Amoroso MR, La Torre G, Esposito F, Landriscina M. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol 2013;7:895-906.

12. Clapham DE. Calcium signaling. Cell 2007;131:1047-58.

13. Fowler MR, Colotti G, Chiancone E, Higuchi Y, Seidler T, Smith GL. Complex modulation of L-type Ca(2+) current inactivation by sorcin in isolated rabbit cardiomyocytes. Pflugers Arch 2009;457:1049-60.

14. Fowler MR, Colotti G, Chiancone E, Smith GL, Fearon IM. Sorcin modulates cardiac L-type Ca2+ current by functional interaction with the alpha1C subunit in rabbits. Exp Physiol 2008;93:1233-8.

15. Franceschini S, Ilari A, Verzili D, Zamparelli C, Antaramian A, Rueda A, Valdivia HH, Chiancone E, Colotti G. Molecular basis for the impaired function of the natural F112L sorcin mutant: X-ray crystal structure, calcium affinity, and interaction with annexin VII and the ryanodine receptor. FASEB J 2008;22:295-306.

16. Matsumoto T, Hisamatsu Y, Ohkusa T, Inoue N, Sato T, Suzuki S, Ikeda Y, Matsuzaki M. Sorcin interacts with sarcoplasmic reticulum Ca(2+)-ATPase and modulates excitation-contraction coupling in the heart. Basic Res Cardiol 2005;100:250-62.

17. Meyers MB, Fischer A, Sun YJ, Lopes CM, Rohacs T, Nakamura TY, Zhou YY, Lee PC, Altschuld RA, McCune SA, Coetzee WA, Fishman GI. Sorcin regulates excitation-contraction coupling in the heart. J Biol Chem 2003;278:28865-71.

18. Suarez J, McDonough PM, Scott BT, Suarez-Ramirez A, Wang H, Fricovsky ES, Dillmann WH. Sorcin modulates mitochondrial Ca(2+) handling and reduces apoptosis in neonatal rat cardiac myocytes. Am J Physiol Cell Physiol 2013;304:C248-56.

19. Zamparelli C, Macquaide N, Colotti G, Verzili D, Seidler T, Smith GL, Chiancone E. Activation of the cardiac Na(+)-Ca(2+) exchanger by sorcin via the interaction of the respective Ca(2+)-binding domains. J Mol Cell Cardiol 2010;49:132-41.

20. Marmugi A, Parnis J, Chen X, Carmichael L, Hardy J, Mannan N, Marchetti P, Piemonti L, Bosco D, Johnson P, Shapiro JA, Cruciani-Guglielmacci C, Magnan C, Ibberson M, Thorens B, Valdivia HH, Rutter GA, Leclerc I. Sorcin links pancreatic β-cell lipotoxicity to ER Ca2+ stores. Diabetes 2016;65:1009-21.

21. Noordeen NA, Meur G, Rutter GA, Leclerc I. Glucose-induced nuclear shuttling of ChREBP is mediated by sorcin and Ca(2+) ions in pancreatic beta-cells. Diabetes 2012;61:574-85.

22. Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng T, Yang M, Xiong D. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 2013;72:789-98.

23. Anthony DF, Beattie J, Paul A, Currie S. Interaction of calcium/calmodulin-dependent protein kinase IIdeltaC with sorcin indirectly modulates ryanodine receptor function in cardiac myocytes. J Mol Cell Cardiol 2007;43:492-503.

24. Salzer U, Hinterdorfer P, Hunger U, Borken C, Prohaska R. Ca(++)-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VII), and sorcin. Blood 2002;99:2569-77.

25. Brownawell AM, Creutz CE. Creutz, Calcium-dependent binding of sorcin to the N-terminal domain of synexin (annexin VII). J Biol Chem 1997;272:22182-90.

26. Tomas A, Futter C, Moss SE. Moss, Annexin 11 is required for midbody formation and completion of the terminal phase of cytokinesis. J Cell Biol 2004;165:813-22.

27. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med 2011;6:481-92.

28. Buschow SI, van Balkom BW, Aalberts M, Heck AJ, Wauben M, Stoorvogel W. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol Cell Biol 2010;88:851-6.

29. Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC, Coffey RJ. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 2013;12:343-55.

30. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS, Knepper MA. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 2009;20:363-79.

31. Keerthikumar S, Gangoda L, Liem M, Fonseka P, Atukorala I, Ozcitti C, Mechler A, Adda CG, Ang CS, Mathivanan S. Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes. Oncotarget 2015;6:15375-96.

32. Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget 2015;6:21740-54.

33. Liang B, Peng P, Chen S, Li L, Zhang M, Cao D, Yang J, Li H, Gui T, Li X, Shen K. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics 2013;80:171-82.

34. Pienimaeki-Roemer A, Kuhlmann K, Böttcher A, Konovalova T, Black A, Orsó E, Liebisch G, Ahrens M, Eisenacher M, Meyer HE, Schmitz G. Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets. Transfusion 2015;55:507-21.

35. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 2004;101:13368-73.

36. Ali R, Huang Y, Maher SE, Kim RW, Giordano FJ, Tellides G, Geirsson A. miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. J Mol Cell Cardiol 2012;52:1027-37.

37. Bers DM, Despa S, Bossuyt J. Regulation of Ca2+ and Na+ in normal and failing cardiac myocytes. Ann N Y Acad Sci 2006;1080:165-77.

38. Seidler T, Miller SL, Loughrey CM, Kania A, Burow A, Kettlewell S, Teucher N, Wagner S, Kögler H, Meyers MB, Hasenfuss G, Smith GL. Effects of adenovirus-mediated sorcin overexpression on excitation-contraction coupling in isolated rabbit cardiomyocytes. Circ Res 2003;93:132-9.

39. Lokuta AJ, Meyers MB, Sander PR, Fishman GI, Valdivia HH. Modulation of cardiac ryanodine receptors by sorcin. J Biol Chem 1997;272:25333-8.

40. Collis LP, Meyers MB, Zhang J, Phoon CK, Sobie EA, Coetzee WA, Fishman GI. Expression of a sorcin missense mutation in the heart modulates excitation-contraction coupling. FASEB J 2007;21:475-87.

41. Farrell EF, Antaramian A, Rueda A, Gómez AM, Valdivia HH. Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart. J Biol Chem 2003;278:34660-6.

42. Frank KF, Bölck B, Ding Z, Krause D, Hattebuhr N, Malik A, Brixius K, Hajjar RJ, Schrader J, Schwinger RH. Overexpression of sorcin enhances cardiac contractility in vivo and in vitro. J Mol Cell Cardiol 2005;38:607-15.

43. Suarez J, Belke DD, Gloss B, Dieterle T, McDonough PM, Kim YK, Brunton LL, Dillmann WH. In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2004;286:H68-75.

44. Chen X, Weber C, Farrell ET, Alvarado FJ, Zhao YT, Gómez AM, Valdivia HH. Sorcin ablation plus beta-adrenergic stimulation generate an arrhythmogenic substrate in mouse ventricular myocytes. J Mol Cell Cardiol 2018;114:199-210.

45. Alzheimer's Association Calcium Hypothesis Workgroup. Calcium hypothesis of Alzheimer's disease and brain aging: a framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimers Dement 2017;13:178-182.e17.

46. Surmeier DJ, Halliday GM, Simuni T. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. Exp Neurol 2017;298:202-9.

47. Del Prete D, Checler F, Chami M. Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegener 2014;9:21.

48. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE, Kim TW. Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J Biol Chem 2000;275:14440-5.

49. Woods WS, Boettcher JM, Zhou DH, Kloepper KD, Hartman KL, Ladror DT, Qi Z, Rienstra CM, George JM. Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J Biol Chem 2007;282:34555-67.

50. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 2006;126:981-93.

51. Takeda T, Asahi M, Yamaguchi O, Hikoso S, Nakayama H, Kusakari Y, Kawai M, Hongo K, Higuchi Y, Kashiwase K, Watanabe T, Taniike M, Nakai A, Nishida K, Kurihara S, Donoviel DB, Bernstein A, Tomita T, Iwatsubo T, Hori M, Otsu K. Presenilin 2 regulates the systolic function of heart by modulating Ca2+ signaling. FASEB J 2005;19:2069-71.

52. Kim SI, Lee HJ, Kim SS, Kwon YS, Chun W. Sequestration of sorcin by aberrant forms of tau results in the defective calcium homeostasis. Korean J Physiol Pharmacol 2016;20:387-97.

53. Xie H, Chang M, Hu X, Wang D, Tian M, Li G, Jiang H, Wang Y, Dong Z, Zhang Y, Hu L. Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells. Neurol Sci 2011;32:221-8.

54. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 2008;6:8.

55. Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, Zhang J. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 2006;5:1193-204.

56. Andreev VP, Petyuk VA, Brewer HM, Karpievitch YV, Xie F, Clarke J, Camp D, Smith RD, Lieberman AP, Albin RL, Nawaz Z, El Hokayem J, Myers AJ. Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains. J Proteome Res 2012;11:3053-67.

57. Musunuri S, Wetterhall M, Ingelsson M, Lannfelt L, Artemenko K, Bergquist J, Kultima K, Shevchenko G. Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry. J Proteome Res 2014;13:2056-68.

58. Seyfried NT, Dammer EB, Swarup V, Nandakumar D, Duong DM, Yin L, Deng Q, Nguyen T, Hales CM, Wingo T, Glass J, Gearing M, Thambisetty M, Troncoso JC, Geschwind DH, Lah JJ, Levey AI. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's disease. Cell Syst 2017;4:60-72.e4.

59. Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X, Shao Y, Safar JG, Ueberheide B, Wisniewski T. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. Acta Neuropathol 2017;133:933-54.

60. Hondius DC, Eigenhuis KN, Morrema THJ, van der Schors RC, van Nierop P, Bugiani M, Li KW, Hoozemans JJM, Smit AB, Rozemuller AJM. Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol Commun 2018;6:46.

61. Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, Seyfried NT. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 2018;10:48-62.

62. Kalathur RK, Giner-Lamia J, Machado S, Barata T, Ayasolla KR, Futschik ME. The unfolded protein response and its potential role in Huntington's disease elucidated by a systems biology approach. Version 2. F1000Res 2015;4:103.

63. Gracy KN, Clarke CL, Meyers MB, Pickel VM. N-methyl-D-aspartate receptor 1 in the caudate-putamen nucleus: ultrastructural localization and co-expression with sorcin, a 22,000 mol. wt calcium binding protein. Neuroscience 1999;90:107-17.

64. Clemen CS, Herr C, Hövelmeyer N, Noegel AA. The lack of annexin A7 affects functions of primary astrocytes. Exp Cell Res 2003;291:406-14.

65. Meyers MB, Biedler JL. Increased synthesis of a low molecular weight protein in vincristine-resistant cells. Biochem Biophys Res Commun 1981;99:228-35.

66. Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H, Borst P. Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988;48:5927-32.

67. Deng L, Su T, Leng A, Zhang X, Xu M, Yan L, Gu H, Zhang G. Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol 2010;27:1102-8.

68. Padar S, van Breemen C, Thomas DW, Uchizono JA, Livesey JC, Rahimian R. Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol 2004;142:305-16.

69. Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C, Zhu Z, Xiong D. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 2006;349:303-9.

70. Qu Y, Yang Y, Liu B, Xiao W. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Med Oncol 2010;27:1303-8.

71. Tan Y, Li G, Zhao C, Wang J, Zhao H, Xue Y, Han M, Yang C. Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 2003;27:125-31.

72. Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, Hatayama T, Nakayama Y. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. Biochem Biophys Res Commun 2014;448:430-6.

73. Yang YX, Chen ZC, Zhang GY, Yi H, Xiao ZQ. A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem 2008;104:1010-21.

74. Zhou Y, Xu Y, Tan Y, Qi J, Xiao Y, Yang C, Zhu Z, Xiong D. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res 2006;30:469-76.

75. Gao Y, Li W, Liu X, Gao F, Zhao X. Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells. Mol Med Rep 2015;11:2118-24.

76. Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun P, Sun H, Ma X, Peng J, Liu K. Targeting P-glycoprotein and SORCIN: dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR. J Cell Physiol 2018;233:3066-79.

77. Dabaghi M, Rahgozar S, Moshtaghian J, Moafi A, Abedi M, Pourabutaleb E. Overexpression of SORCIN is a prognostic biomarker for multidrug-resistant pediatric acute lymphoblastic leukemia and correlates with upregulated MDR1/P-gp. Genet Test Mol Biomarkers 2016;20:516-21.

78. Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V, Matassa DS, Fersini A, Neri V, Esposito F, Landriscina M. Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis. Cancer Res 2011;71:7659-69.

79. Tong W, Sun D, Wang Q, Suo J. Sorcin enhances metastasis and promotes epithelial-to-mesenchymal transition of colorectal cancer. Cell Biochem Biophys 2015;72:453-9.

80. Mangia A, Caldarola L, Dell'Endice S, Scarpi E, Saragoni L, Monti M, Santini D, Brunetti O, Simone G, Silvestris N. The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. Cancer Biol Ther 2015;16:1140-7.

81. Xu P, Jiang YF, Wang JH. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines. Int J Clin Exp Pathol 2015;8:2300-10.

82. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.

83. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005;65:11335-44.

84. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003;22:4918-23.

85. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, Rosenblum M, Mikkelsen T, Fine HA. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.

86. Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K, Sugisaki Y, Onda M, Tsunoda T. Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol 2006;111:29-38.

87. Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F, Colotti G. Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells. Cell Death Dis 2017;8:e2950.

88. Hamada H, Okochi E, Oh-hara T, Tsuruo T. Purification of the Mr 22,000 calcium-binding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res 1988;48:3173-8.

89. He Q, Zhang G, Hou D, Leng A, Xu M, Peng J, Liu T. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011;25:237-43.

90. Kawakami M, Nakamura T, Okamura N, Komoto C, Markova S, Kobayashi H, Hashimoto N, Okumura K, Sakaeda T. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. Biol Pharm Bull 2007;30:1065-73.

91. Liu X, Chen L, Feng B, Liu G. Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma. Anat Rec (Hoboken) 2014;297:215-21.

92. Parekh HK, Deng HB, Choudhary K, Houser SR, Simpkins H. Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells. Biochem Pharmacol 2002;63:1149-58.

93. Gong Z, Sun P, Chu H, Zhu H, Sun D, Chen J. Overexpression of sorcin in multidrug-resistant human breast cancer. Oncol Lett 2014;8:2393-8.

94. Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y, Zhang Y, Yagüe E, Xiong D. Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat 2014;143:287-99.

95. Tuo H, Shu F, She S, Yang M, Zou XQ, Huang J, Hu HD, Hu P, Ren H, Peng SF, Yang YX. Sorcin induces gastric cancer cell migration and invasion contributing to STAT3 activation. Oncotarget 2017;8:104258-71.

96. Li X, Liu Y, Wang Y, Liu J, Li X, Cao H, Gao X, Zheng SJ. Negative regulation of hepatic inflammation by the soluble resistance-related calcium-binding protein via signal transducer and activator of transcription 3. Front Immunol 2017;8:709.

97. Lei X, Liang Y, Chen J, Xiao S, Lei J, Li J, Duanmu J, Jiang Q, Liu D, Tang C, Li T. Sorcin predicts poor prognosis and promotes metastasis by facilitating epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep 2017;7:10049.

98. Gupta K, Sirohi VK, Kumari S, Shukla V, Manohar M, Popli P, Dwivedi A. Sorcin is involved during embryo implantation via activating VEGF/PI3K/Akt pathway in mice. J Mol Endocrinol 2018;60:119-132.

99. Li GY, Zhang L, Liu JZ, Chen SG, Xiao TW, Liu GZ, Wang JX, Wang LX, Hou M. Marine drug Haishengsu increases chemosensitivity to conventional chemotherapy and improves quality of life in patients with acute leukemia. Biomed Pharmacother 2016;81:160-5.

100. Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun P, Sun H, Ma X, Peng J, Liu K. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca(2+) -mediated apoptosis pathways in MCF-7/ADR and K562/ADR. J Cell Physiol 2018;233:3066-79.

101. Li GY, Liu JZ, Zhang B, Yang M, Chen SG, Hou M, Wang LX. Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice. Adv Med Sci 2013;58:112-7.

102. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987;77:142-4.

103. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987;84:265-9.

104. Schoenlein PV. Molecular cytogenetics of multiple drug resistance. Cytotechnology 1993;12:63-89.

105. Scotto KW, Biedler JL, Melera PW. Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 1986;232:751-5.

106. Van der Bliek AM, Van der Velde-Koerts T, Ling V, Borst P. Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol 1986;6:1671-8.

107. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352-6.

108. Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U. Multidrug resistance in locally advanced breast cancer. Tumour Biol 2006;27:309-18.

109. Brügger D, Brischwein K, Liu C, Bader P, Niethammer D, Gekeler V, Beck JF. Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res 2002;22:4229-32.

110. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6.

111. Gekeler V, Frese G, Diddens H, Probst H. Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line. Biochem Biophys Res Commun 1988;155:754-60.

112. Hu XF, Slater A, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 1995;71:931-6.

113. Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol 2002;49:391-7.

114. Park J, Shinohara N, Liebert M, Noto L, Flint A, Grossman HB. P-glycoprotein expression in bladder cancer. J Urol 1994;151:43-6.

115. Schneider J, Efferth T, Centeno MM, Mattern J, Rodríguez-Escudero FJ, Volm M. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 1993;29A:554-8.

116. Flahaut M, Mühlethaler-Mottet A, Martinet D, Fattet S, Bourloud KB, Auderset K, Meier R, Schmutz NB, Delattre O, Joseph JM, Gross N. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. Genes Chromosomes Cancer 2006;45:495-508.

117. Kitada K, Yamasaki T. The MDR1/ABCB1 regional amplification in large inverted repeats with asymmetric sequences and microhomologies at the junction sites. Cancer Genet Cytogenet 2007;178:120-7.

118. Kadioglu O, Efferth T. Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells. Invest New Drugs 2016;34:515-21.

119. Chen GK, Lacayo NJ, Durán GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, Sikic BI. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer 2002;34:372-83.

120. Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Updat 2007;10:51-8.

121. Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M, Hosoda F, Ohki M, Imoto I, Inazawa J, Hirohashi S. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 2005;43:863-74.

122. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 1997;99:1947-57.

123. Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab Invest 2005;85:664-74.

124. Kim IW, Han N, Kim MG, Kim T, Oh JM. Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using the cancer genome Atlas data. Pharmacogenet Genomics 2015;25:1-7.

125. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 2008;10:920-31.

126. Chao CC, Ma CM, Lin-Chao S. Co-amplification and over-expression of two mdr genes in a multidrug-resistant human colon carcinoma cell line. FEBS Lett 1991;291:214-8.

127. Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY, Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, Wang TY, Lee AY. Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents. Cancer Lett 2013;337:218-25.

128. Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, van der Krogt JA, Michaux L, Shetty S, Krenacs L, Tousseyn T, De Paepe P, Uyttebroeck A, Verhoef G, Taghon T, Vandenberghe P, Cools J, Wlodarska I. Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 2014;9:e102977.

129. Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J, Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics 2016;17:442.

130. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Slonimskaya EM, Ibragimova MK, Kazantseva PV, Kzhyshkowska J, Choinzonov EL. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Oncotarget 2016;7:7829-41.

131. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-94.

132. Torigoe K, Sato S, Kusaba H, Kohno K, Kuwano M, Okumura K, Green ED, Tsui LC, Scherer SW, Schlessinger D, Wada M. A YAC-based contig of 1.5 Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human multidrug-resistant cell lines. Genome Res 1995;5:233-44.

133. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007;173:1-9.

134. Januchowski R, Sterzyńska K, Zawierucha P, Ruciński M, Świerczewska M, Partyka M, Bednarek-Rajewska K, Brązert M, Nowicki M, Zabel M, Klejewski A. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget 2017;8:49944-58.

135. Lee S, Kim K, Ho JN, Jin H, Byun SS, Lee E. Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells. Oncol Lett 2017;14:3011-8.

136. Sasi NK, Bhutkar A, Lanning NJ, MacKeigan JP, Weinreich M. DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways. Neoplasia 2017;19:439-50.

137. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat 2017;32:23-46.

138. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 2006;45:365-74.

139. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013;8:e65309.

140. Han C, Yu Z, Duan Z, Kan Q. Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int 2014;2014:428371.

141. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011;4:79.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: